title: Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data.
authors.forename: Andrea
authors.initials: A
authors.lastname: Paradisi
authors.forename: Giacomo
authors.initials: G
authors.lastname: Caldarola
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Capizzi
authors.forename: Massimo
authors.initials: M
authors.lastname: Siciliano
authors.forename: Eleonora
authors.initials: E
authors.lastname: Annichiarico
authors.forename: Fabio Maria
authors.initials: FM
authors.lastname: Vecchio
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Amerio
authors.forename: Clara
authors.initials: C
authors.lastname: De Simone
mesh_terms: D000328:Adult; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy*; D000068800:Etanercept; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept